1298. High Prescription Rate of Medications with Significant Rifampin Drug Interactions in Patients with Diabetic Foot Osteomyelitis: Should Rifabutin be Included in Clinical Trials for Adjunctive Therapy?

BACKGROUND: Diabetic foot osteomyelitis (DFO) is a leading cause of amputations. Rifamycins can penetrate osteoblasts and disrupt biofilm, making them ideal adjunctive antibiotics for DFO. A recent retrospective DFO study found that rifampin adjuvant therapy was associated with significantly higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallarino-Haeger, Christina, Watson, Allison, Mahgoub, Umnia, Francis, Lily, Heydari, Maryam, Choudhary, Muaaz, Kempker, Russell R, Schechter, Marcos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677499/
http://dx.doi.org/10.1093/ofid/ofad500.1137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677499/
http://dx.doi.org/10.1093/ofid/ofad500.1137

Ejemplares similares